Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects With SLE

Next Previous
Trial Profile

A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects With SLE

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 26 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Evobrutinib (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Sponsors EMD Serono; EMD Serono Research & Development Institute; Merck KGaA

    • Most Recent Events

    • 23 Nov 2022 Results of the integrated safety (n=1083) profile of evobrutinib using pooled data from (NCT02975349, NCT03233230, NCT02975336) multiple sclerosis (MS), rheumatoid arthritis and systemic lupus erythematosus trials, published in the Journal of Neurology, Neurosurgery and Psychiatry.
    • 14 Nov 2022 Results of post hoc pooled analysis assessing the responsiveness of the PROMIS Fatigue 13a and 10a scores and to establish minimal important difference (MID) estimates in SLE populations, presented at the ACR Convergence 2022.
    • 28 Jun 2022 Results of a post hoc analysis presented at the 8th Congress of the European Academy of Neurology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top